Maravai LifeSciences Holdings, Inc.

MRVI

US56600D1072

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-05 pm EDT			5-day change	1st Jan Change
6.99 ^USD	0.00%		-2.37%	+6.72%

Jul. 01	Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 3000E Value Index	CI
Jul. 01	Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 1000 Dynamic Index	CI

Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell Midcap Value Index

July 30, 2024

Latest news about Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 3000E Value Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 1000 Dynamic Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell Midcap Growth Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 1000 Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) added to Russell 2000 Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 1000 Value Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell Midcap Value Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 3000 Value Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 2500 Value Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) added to Russell 2000 Growth Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell Midcap Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) added to Russell 2000 Dynamic Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell 1000 Growth Index	Jun. 30	CI
Maravai LifeSciences Holdings, Inc.(NasdaqGS:MRVI) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
Maravai Lifesciences Holdings, Inc. Announces Resignation of Anat Ashkenazi as Director, Effective July 31,2024	Jun. 12	CI
Transcript : Maravai LifeSciences Holdings, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 01:20 PM	Jun. 11
Transcript : Maravai LifeSciences Holdings, Inc. Presents at 2024 RBC Capital Markets Global Healthcare Conference, May-15-2024 03:35 PM	May. 15
UBS Raises Price Target on Maravai LifeSciences to $8.50 From $6.50, Maintains Neutral Rating	May. 09	MT
Baird Adjusts Price Target on Maravai LifeSciences to $10 From $8, Keeps Outperform Rating	May. 09	MT
Earnings Flash (MRVI) MARAVAI LIFESCIENCES HOLDINGS LLC Reports Q1 Revenue $64.2M, vs. Street Est of $60.5M	May. 08	MT
Transcript : Maravai LifeSciences Holdings, Inc., Q1 2024 Earnings Call, May 08, 2024	May. 08
Maravai LifeSciences Holdings, Inc. Reaffirms Financial Guidance for the Full Year 2024	May. 08	CI
Maravai LifeSciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 08	CI
Maravai LifeSciences Unit Opens New Manufacturing Facility in San Diego	Apr. 18	MT
Craig-Hallum Initiates Coverage on Maravai LifeSciences With Buy Rating, $15 Price Target	Apr. 10	MT

Chart Maravai LifeSciences Holdings, Inc.

Duration

Period

Chart Maravai LifeSciences Holdings, Inc.

More charts

Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enable the development of drug therapies, diagnostics and vaccines and to support research on human diseases. Its companies provide products and services in the fields of nucleic acid synthesis and biologics safety testing to various biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. The Company operates through two segments. Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acid products to support the needs of customer research, therapeutic and vaccine programs. The segment also provides research products for labeling and detecting proteins in cells and tissue samples. Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities.

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Maravai LifeSciences Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

6.99 USD

Average target price

10.69 USD

Spread / Average Target

+52.98%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Diagnostics & Testing

	1st Jan change	Capi.
MARAVAI LIFESCIENCES HOLDINGS, INC.	+6.72%	928M
EXACT SCIENCES CORPORATION	-39.75%	7.97B
IOVANCE BIOTHERAPEUTICS, INC.	-10.46%	2.07B
BGI GENOMICS CO., LTD.	-27.73%	1.77B
VERACYTE, INC.	-21.74%	1.64B
CAREDX, INC	+29.42%	777M
SEEGENE, INC.	-8.30%	696M
ADAPTIVE BIOTECHNOLOGIES CORPORATION	-27.76%	500M
CURIOX BIOSYSTEMS CO., LTD	-12.92%	245M
HLB BIOSTEP CO.,LTD.	-1.29%	163M

Bio Diagnostics & Testing